Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused o ...